Journal: Oncology Letters

Article Title: CXCL5 as an autocrine or paracrine cytokine is associated with proliferation and migration of hepatoblastoma HepG2 cells

doi: 10.3892/ol.2017.7236

Figure Lengend Snippet: Primer sequences used for reverse transcription-polymerase chain reaction.

Article Snippet: The secretion levels of CXCL5 were determined by ELISA using Human CXCL5 Elisa kit (cat. no. EK0728; Wuhan Boster Biological Technology, Ltd.), according to the manufacturer's protocol.

Techniques: Sequencing

Journal: Oncology Letters

Article Title: CXCL5 as an autocrine or paracrine cytokine is associated with proliferation and migration of hepatoblastoma HepG2 cells

doi: 10.3892/ol.2017.7236

Figure Lengend Snippet: Reverse transcription-polymerase chain reaction conditions for each primer set.

Article Snippet: The secretion levels of CXCL5 were determined by ELISA using Human CXCL5 Elisa kit (cat. no. EK0728; Wuhan Boster Biological Technology, Ltd.), according to the manufacturer's protocol.

Techniques: Reverse Transcription Polymerase Chain Reaction

Journal: Oncology Letters

Article Title: CXCL5 as an autocrine or paracrine cytokine is associated with proliferation and migration of hepatoblastoma HepG2 cells

doi: 10.3892/ol.2017.7236

Figure Lengend Snippet: CXCL5 and its receptor CXCR2 are expressed by parental, HepG2-NEG and HepG2-A1113 cells. (A) CXCL5 mRNA was upregulated in HepG2-A1113 cells compared with HepG2-parental or HepG2-NEG cells. The expression levels of CXCR2 (A) mRNA and (B) protein were not significantly different in all three cell lines. (C) However, the expression of CXCL5 secretory protein was upregulated in HepG2-A1113 cells compared with HepG2-parental or HepG2-NEG cells. *P<0.05. CXCL5, C-X-C motif chemokine ligand 5; CXCR2, C-X-C chemokine receptor type 2; HepG2-NEG, empty vector-transfected HepG2 cells; HepG2-A1113, CXCL5-transfected HepG2 cells.

Article Snippet: The secretion levels of CXCL5 were determined by ELISA using Human CXCL5 Elisa kit (cat. no. EK0728; Wuhan Boster Biological Technology, Ltd.), according to the manufacturer's protocol.

Techniques: Expressing, Plasmid Preparation, Transfection

Journal: Oncology Letters

Article Title: CXCL5 as an autocrine or paracrine cytokine is associated with proliferation and migration of hepatoblastoma HepG2 cells

doi: 10.3892/ol.2017.7236

Figure Lengend Snippet: Exogenous CXCL5 expression contributes to the tumorigenesis of HepG2 cells in vitro. (A) Cell counting kit-8 assay showed significant growth promotion when HepG2 cells grew in medium supplemented with 20 ng/ml exogenous CXCL5 for 48, 72 or 96 h or 40 ng/ml exogenous CXCL5 for 72 or 96 h; 60 ng/ml exogenous CXCL5 significantly inhibited proliferation only after 96 h of treatment (*P<0.05 vs. 0, 40 or 60 ng/ml; &P<0.05 vs. 0 or 60 ng/ml; #P<0.05 vs. 0, 20 or 40 ng/ml). (B) Treatment with 60 ng/ml exogenous CXCL5 efficiently promoted colony formation of HepG2 cells after 12 days (*P<0.05). (C) Representative images indicated that exogenous CXCL5 at certain concentrations significantly enhanced the migration of HepG2 cells in a Transwell assay (*P<0.05 vs. 0, 20, 60 or 80 ng/ml; &P<0.05 vs. 0 or 20 ng/ml). CXCL5, C-X-C motif chemokine ligand 5.

Article Snippet: The secretion levels of CXCL5 were determined by ELISA using Human CXCL5 Elisa kit (cat. no. EK0728; Wuhan Boster Biological Technology, Ltd.), according to the manufacturer's protocol.

Techniques: Expressing, In Vitro, Cell Counting, Migration, Transwell Assay

Journal: Oncology Letters

Article Title: CXCL5 as an autocrine or paracrine cytokine is associated with proliferation and migration of hepatoblastoma HepG2 cells

doi: 10.3892/ol.2017.7236

Figure Lengend Snippet: Overexpression of CXCL5 is positively associated with the oncogenic potential of HepG2 cells in vitro. (A) Growth, (B) colony formation and (C) migration assays showed the growth, colony formation and migration, respectively, of HepG2-A1113 cells were significantly increased compared with HepG2-parental or HepG2-NEG cells (*P<0.05). CXCL5, C-X-C motif chemokine ligand 5.

Article Snippet: The secretion levels of CXCL5 were determined by ELISA using Human CXCL5 Elisa kit (cat. no. EK0728; Wuhan Boster Biological Technology, Ltd.), according to the manufacturer's protocol.

Techniques: Over Expression, In Vitro, Migration

Journal: Oncology Letters

Article Title: CXCL5 as an autocrine or paracrine cytokine is associated with proliferation and migration of hepatoblastoma HepG2 cells

doi: 10.3892/ol.2017.7236

Figure Lengend Snippet: Upregulation of CXCL5 in LX-2 cells is involved in the proliferation and migration of HepG2 cells by paracrine signaling. CXCL5 (A) mRNA and (B) secretory protein in LX-2 A1113 cells were significantly increased compared with parental and LX-2 NEG cells (*P<0.05). The (C) proliferation and (D) migration capacity of HepG2 cells treated with CM from LX-2 A1113 cells were increased compared with the cells treated with CM from LX-2 parental or LX-2 NEG cells (*P<0.05). CXCL5, C-X-C motif chemokine ligand 5; LX-2 A1113, CXCL5-transfected LX-2 cells; LX-2 NEG, empty vector-transfected LX-2 cells; CM, culture medium.

Article Snippet: The secretion levels of CXCL5 were determined by ELISA using Human CXCL5 Elisa kit (cat. no. EK0728; Wuhan Boster Biological Technology, Ltd.), according to the manufacturer's protocol.

Techniques: Migration, Transfection, Plasmid Preparation

Journal: Oncology Letters

Article Title: CXCL5 as an autocrine or paracrine cytokine is associated with proliferation and migration of hepatoblastoma HepG2 cells

doi: 10.3892/ol.2017.7236

Figure Lengend Snippet: Overexpression of CXCL5 regulates the expression of genes in HepG2 cells. (A) In reverse transcription-polymerase chain reaction assays, downregulation of NDRG3, Bax and P53 mRNA in HepG2-A1113 cells were detected compared with HepG2-parental or HepG2-NEG cells. However, the levels of Bcl-2 and VEGF mRNA in HepG2-A1113 cells were increased. (B) Western blotting assays showed upregulation of IL-18, IL-1β and CSE proteins in HepG2-A1113 cells (*P<0.01; &P<0.05). Bcl-2, B-cell lymphoma-2; Bax, Bcl-2-associated X protein; VEGF, vascular endothelial growth factor; IL, interleukin; CXCL5, C-X-C motif chemokine ligand 5; CSE, cystathionine-γ-lyase; HepG2-NEG, empty vector-transfected HepG2 cells; HepG2-A1113, CXCL5-transfected HepG2 cells.

Article Snippet: The secretion levels of CXCL5 were determined by ELISA using Human CXCL5 Elisa kit (cat. no. EK0728; Wuhan Boster Biological Technology, Ltd.), according to the manufacturer's protocol.

Techniques: Over Expression, Expressing, Reverse Transcription, Polymerase Chain Reaction, Western Blot, Plasmid Preparation, Transfection

Journal: bioRxiv

Article Title: Immune-Epithelial Interactions via TGF-β Orchestrates Stem-Cell Niche Formation and Morphogenesis

doi: 10.1101/2025.05.22.655596

Figure Lengend Snippet: (a) Cytokine array profiling comparing co-cultures and epithelial-alone hydrogels shows elevated levels of IL-6, CXCL5, CCL2, TIMP-1, LIF, GRO-a (CXCL1), IL-8, IGFBP-1, IGFBP-2, VEGF-A, SDF-1a, and IGF-1in responder co-cultures with immune cells (n=2 patients). (b) Bar graph showing treatment of responder epithelial cells with individual (IL-6, CCL2, GRO-a (CXCL1), CXCL5, VEGF) or pooled recombinant cytokines at 2ng/ml. (n=8; ns, not significant, **p-value < 0.01, ***p-value < 0.001). (c) Bar graph showing treatment of responder epithelium with conditioned media from responder co-cultures (n=8, ns, not significant). (d) Flow cytometry analysis of patient single cells showing percent of CD45 immune cells out of all breast cells. (n=12; ns, not significant). (e) Bar graph and scatter plot showing percent of CD3 + CD4 - CD8 - double negative (DN) T cells out of all CD45 + immune cells (n=12; ***p-value < 0.001, two-tailed t-test). (f) Scatter plot showing percent of γδ T cells out of all DN T cells.

Article Snippet: For treatment with recombinant proteins IL-6 (PHC0066, Thermofisher,2ng/ml), CCL2 (279-MC-050/CF, R&D Systems, 2ng/ml), GRO-a (275-GR-010/CF, R&D Systems, 2ng/ml), CXCL5 (254-XB-025/CF, R&D Systems, 2ng/ml), VEGF (78073, Stem Cell Technologies, 2ng/ml), treatment began at timepoint 0 and continued for the entire culture period.

Techniques: Recombinant, Flow Cytometry, Two Tailed Test

Journal: PLoS ONE

Article Title: Tumour Tissue Microenvironment Can Inhibit Dendritic Cell Maturation in Colorectal Cancer

doi: 10.1371/journal.pone.0027944

Figure Lengend Snippet: Concentrations of CCL2, CXCL1, CXCL5 and VEGF in tumour conditioned media of 21 colorectal cancer patients were measured by ELISA. The concentrations of CCL2, CXCL1 and CXCL5 correlated with expression of CD83 on DCs treated with TCM (A). CCL2, CXCL1 and CXCL5 inversely correlated with secretion of IL-12p70 from dendritic cells treated with the TCM (B). The Spearman rank correlation test was used.

Article Snippet: In separate experiments 1×10 5 iDC/200 μl media were treated with human recombinant 50 ng/mL CCL2 (MCP-1), 100 ng/mL CXCL1 (GROα), 100 ng/mL CXCL5 (ENA-78) and 20 ng/mL VEGF (R&D Systems, Abingdon, UK) for 4 hours before 1 μg/mL LPS was added to the samples.

Techniques: Enzyme-linked Immunosorbent Assay, Expressing

Journal: PLoS ONE

Article Title: Tumour Tissue Microenvironment Can Inhibit Dendritic Cell Maturation in Colorectal Cancer

doi: 10.1371/journal.pone.0027944

Figure Lengend Snippet: The supernatants of the DCs cultured in the presence of CCL2, CXCL1, CXCL5 and VEGF (n = 8) were harvested and concentrations of IL-10 and IL-12p70 determined by ELISA. Statistical significance was determined by the Mann-Whitney U test. * p<0.05, ** p<0.01.

Article Snippet: In separate experiments 1×10 5 iDC/200 μl media were treated with human recombinant 50 ng/mL CCL2 (MCP-1), 100 ng/mL CXCL1 (GROα), 100 ng/mL CXCL5 (ENA-78) and 20 ng/mL VEGF (R&D Systems, Abingdon, UK) for 4 hours before 1 μg/mL LPS was added to the samples.

Techniques: Cell Culture, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY